Results 61 to 70 of about 38,272 (314)

Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus

Therapeutic Advances in Endocrinology and Metabolism, 2015
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a novel class of antihyperglycaemic agents with an insulin-independent mode of action. Dapagliflozin is a member of the SGLT2 inhibitors class that has received marketing authorization in Europe and ...
Aris Liakos, Thomas Karagiannis, Eleni Bekiari, Panagiota Boura, Apostolos Tsapas   +4 more
doaj   +1 more source

Активность аденозинмонофосфатактивированной протеинкиназы в лимфоцитах при действии сахароснижающих препаратов [PDF]

, 2017
Изучали активность аденозинмонофосфатактивируемой протеинкиназы (АМРК), контролирующей энергетический баланс клетки, при лечении больных диабетом сахароснижающими препаратами.
Бельчина, Ю.Б., Пушкарев, В.В., Пушкарев, В.М., Соколова, Л.К., Тронько, Н.Д.   +4 more
core   +1 more source

Dapagliflozin improves diabetic kidney disease by inhibiting ferroptosis through β-hydroxybutyrate production

Renal Failure
Background Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease. Sodium-glucose cotransporter protein 2 inhibitors (SGLT2i) are antihyperglycemic agents that provide additional renal-protective effects in patients with DKD ...
Yan Tian, Chenxia Zhou, Qun Yan, Ziyi Li, Da Chen, Bo Feng, Jun Song   +6 more
semanticscholar   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Dapagliflozin induces vasodilation in resistance-size mesenteric arteries by stimulating smooth muscle cell KV7 ion channels

Heliyon, 2022
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that, in addition to glucose reduction, lowers systemic blood pressure. Here, we investigated if dapagliflozin could directly relax small mesenteric arteries that control peripheral ...
Ahasanul Hasan, Sreelakshmi N. Menon, Farzana Zerin, Raquibul Hasan   +3 more
doaj   +1 more source

Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 799-808, April 2025.
Abstract We performed a systematic review and meta‐analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023.
Shuo Xu, Zhenbang Gu, Wengen Zhu, Shenghui Feng   +3 more
wiley   +1 more source

Indirect comparison of SGLT2 inhibitors in patients with established heart failure: evidence based on Bayesian methods

ESC Heart Failure, 2023
Aims Head‐to‐head comparisons among SGLT2 inhibitors treatments in established heart failure remain absent. We conducted a systematic review of dedicated heart failure trials to assess indirectly the composite outcomes and individual clinical endpoints ...
Hai‐Bin Chen, Yao‐Lin Yang, Rong‐Sen Meng, Xue‐Wei Liu   +3 more
doaj   +1 more source

SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus : a systematic review and network meta-analysis [PDF]

, 2016
Objective Because of the lack of head-to-head trials, the aim was to indirectly compare sodium glucose transporter-2 (SGLT-2) inhibitors in the treatment of type 2 diabetes. Design Systematic review and network meta-analysis.
Shyangdan, Deepson S., Uthman, Olalekan A., Waugh, Norman   +2 more
core   +1 more source

Comparative Outcomes of Empagliflozin to Dapagliflozin in Patients With Heart Failure

JAMA Network Open
Key Points Question What are the comparative outcomes of empagliflozin and dapagliflozin in reducing all-cause mortality and hospitalizations in patients with heart failure?
Katherine L. Modzelewski, Alexandra Pipilas, N. Bosch   +2 more
semanticscholar   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source